A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK under a new agreement. The Phase IIb LIBERATE study will test the tolerance and the efficacy of glenzocimab 1000mg to reduce heart damage following a myocardial infarction (MI). According to the partnership between the University of […]